Assessment of the recoverability of
investments in subsidiaries' shares
Net book value of investments in shares in
subsidiaries as of 31 December 2024,
amounted to PLN 6,146 million, which
represents 12% of the Company's total
assets, including:
•
investment in shares of Future 1
Sp. z o.o. amounted to PLN 4,175
million,
•
investment in shares of KGHM
Metraco S.A. amounted to PLN
421 million,
•
remaining investment in stocks
and shares of companies
amounted to PLN 1,550 million.
Investments in shares and stocks in
subsidiaries are carried at acquisition cost
less impairment lossess. Accounting
policies and disclosures concerning
investments in shares and stocks in
subsidiaries are included in note 6.1 to the
annual separate financial statements.
As at 31 December 2024, the Company
identified triggers for impairment in
relation to the following investments in
shares in subsidiaries:
a) Pol-Miedź Trans Sp. z o.o.,
b) PeBeKa S.A.,
c) Zagłębie Lubin S.A.,
d) INVEST PV 7 Sp. z o.o.,
e) INVEST PV 40 Sp. z o.o.,
f) INVEST PV 58 Sp. z o.o.,
g) INVEST PV 59 Sp. z o.o.,
h) Future 1 Sp. z o.o.
As a result of the tests conducted, a total
impairment write-down of PLN 154 million
was recognized in the standalone financial
statements for investments in shares in
subsidiaries, including:
a) Pol-Miedź Trans Sp. z o.o. in the
amount of PLN 90 million,
b) Zagłębie Lubin S.A. in the amount of
PLN 25.2 million,
Our testing procedures included in particular:
•
verification of compliance of the adopted valuation
principle with applicable accounting standards,
•
understanding and assessing the process of
identification by the Management Board of triggers
for occurrence or reversal of impairment of
investments in subsidiaries,
•
understanding and assessing the correctness of
the methods used to conduct impairment tests in
accordance with the relevant financial reporting
standards,
•
the evaluation of the work performed by external
experts utilized by the Company's Management
Board, including their competence and
independence,
•
checking mathematical correctness and
methodological consistency (using internal
valuation experts) of the recoverable amount
valuation models prepared by the Company's
Management Board,
•
critical assessment of the assumptions adopted by
the Company's Management Board and estimates
made to determine the recoverable amount,
including, among others:
o
the projection period of future cash flows
based on the approved budgets for
companies for which an impairment test
was performed and the level of revenues,
operating margin and future investment
expenditures assumed therein,
o
discount rate used (based on the
weighted average cost of capital),
o
○residual value, including the residual
growth rate after the forecast period.
•
assessment of the sensitivity analysis of the
adopted assumptions on the valuation result
carried out by the Management Board,